Arbutus Biopharma Corporation

NasdaqGS:ABUS Stock Report

Market Cap: US$470.3m

Arbutus Biopharma Past Earnings Performance

Past criteria checks 0/6

Arbutus Biopharma has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 38.2% per year.

Key information

11.2%

Earnings growth rate

33.7%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate38.2%
Return on equity-68.7%
Net Margin-401.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

May 21
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Bio slips 4% as Q1 revenue trails consensus

May 05

What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

Mar 12
What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Feb 02
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Jan 07
Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Arbutus Biopharma (ABUS) Investor Presentation - Slideshow

Dec 17

What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Dec 12
What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Revenue & Expenses Breakdown
Beta

How Arbutus Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ABUS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2318-73220
30 Sep 2322-75220
30 Jun 2324-73190
31 Mar 2333-70180
31 Dec 2239-69180
30 Sep 2236-69180
30 Jun 2233-76190
31 Mar 2221-85180
31 Dec 2111-88170
30 Sep 2110-87160
30 Jun 218-84160
31 Mar 218-79150
31 Dec 207-76150
30 Sep 206-83130
30 Jun 208-147100
31 Mar 207-156130
31 Dec 196-165140
30 Sep 196-158180
30 Jun 195-100200
31 Mar 195-73170
31 Dec 186-67160
30 Sep 187-83140
30 Jun 1812-68150
31 Mar 1812-86150
31 Dec 1711-85160
30 Sep 178-267160
30 Jun 172-275140
31 Mar 171-387150
31 Dec 161-384130
30 Sep 1614-171140
30 Jun 1618-180120
31 Mar 1621-65140
31 Dec 1523-63260
30 Sep 1517-62130
30 Jun 1517-42150
31 Mar 1515-3390
31 Dec 1415-3990
30 Sep 1418-3580
30 Jun 1417-3380
31 Mar 1418-3070
31 Dec 1315-1460
30 Sep 13122650
30 Jun 13122960
31 Mar 13133070

Quality Earnings: ABUS is currently unprofitable.

Growing Profit Margin: ABUS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ABUS is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.

Accelerating Growth: Unable to compare ABUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: ABUS has a negative Return on Equity (-68.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.